Pediatrix Medical (MD)
Market Price (9/5/2026): $27.04 | Market Cap: $2.1 BilSector: Health Care | Industry: Health Care Services
Pediatrix Medical (MD)
Market Price (9/5/2026): $27.04Market Cap: $2.1 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.1%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.7%, FCF Yield is 11% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% Low stock price volatilityVol 12M is 42% Megatrend and thematic driversMegatrends include Specialized Healthcare Delivery. Themes include Neonatal & Pediatric Intensive Care, Maternal-Fetal Medicine, and Pediatric Subspecialty Services. | Trading close to highsDist 52W High is -1.3%, Dist 3Y High is -1.3% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.7% Key risksMD key risks include [1] margin pressure from rising clinical compensation costs and [2] a shrinking top-line revenue resulting from its strategic divestiture of lower-margin practices. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.1%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.7%, FCF Yield is 11% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Low stock price volatilityVol 12M is 42% |
| Megatrend and thematic driversMegatrends include Specialized Healthcare Delivery. Themes include Neonatal & Pediatric Intensive Care, Maternal-Fetal Medicine, and Pediatric Subspecialty Services. |
| Trading close to highsDist 52W High is -1.3%, Dist 3Y High is -1.3% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.7% |
| Key risksMD key risks include [1] margin pressure from rising clinical compensation costs and [2] a shrinking top-line revenue resulting from its strategic divestiture of lower-margin practices. |
Qualitative Assessment
AI Analysis | Feedback
Pediatrix Medical (MD) stock has gained about 25% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat and Reaffirmed Guidance. Pediatrix Medical Group reported Adjusted EPS of $0.63 for fiscal Q2 2026 (ended June 30, 2026), surpassing analyst estimates of $0.59 by 6.6%. Revenue for the quarter reached $488 million, exceeding the consensus estimate of $477.8 million by 2.1%. Furthermore, the company reaffirmed its full-year 2026 Adjusted EBITDA guidance in the range of $280 million to $300 million, which helped instill investor confidence.
2. Favorable Payer Mix and Reimbursement Trends. During fiscal Q2 2026, Pediatrix experienced a 4.0% increase in same-unit revenue from net reimbursement-related factors. This growth was driven by improved cash collections and a favorable shift in payor mix, with commercial and other non-government payors increasing by 135 basis points year-over-year. Notably, the company stated it did not experience the unfavorable payor mix shifts reported by other healthcare sector participants.
Show more
Pediatrix Medical (MD) stock has gained about 25% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat and Reaffirmed Guidance. Pediatrix Medical Group reported Adjusted EPS of $0.63 for fiscal Q2 2026 (ended June 30, 2026), surpassing analyst estimates of $0.59 by 6.6%. Revenue for the quarter reached $488 million, exceeding the consensus estimate of $477.8 million by 2.1%. Furthermore, the company reaffirmed its full-year 2026 Adjusted EBITDA guidance in the range of $280 million to $300 million, which helped instill investor confidence.
2. Favorable Payer Mix and Reimbursement Trends. During fiscal Q2 2026, Pediatrix experienced a 4.0% increase in same-unit revenue from net reimbursement-related factors. This growth was driven by improved cash collections and a favorable shift in payor mix, with commercial and other non-government payors increasing by 135 basis points year-over-year. Notably, the company stated it did not experience the unfavorable payor mix shifts reported by other healthcare sector participants.
3. Significant Share Repurchase Program. Pediatrix demonstrated its commitment to shareholder returns by utilizing $42.7 million to repurchase approximately 2 million shares of its common stock during fiscal Q2 2026. This action contributed to a total of 7 million shares repurchased since August 2025, reducing the total shares outstanding to 81 million and providing an artificial floor for earnings per share.
4. Operational Discipline and Strategic Initiatives. The company maintained operational discipline by keeping clinical salary increases within a tight 3% to 3.5% band during fiscal Q2 2026, which helped stabilize Adjusted EBITDA margins despite modest volume declines. Additionally, Pediatrix is progressing with strategic initiatives, including building a national telemedicine platform to augment its physical services and leveraging its multi-state footprint in maternal-fetal medicine and neonatal intensive care units.
Show less
Stock Movement Drivers
Fundamental Drivers
The 25.5% change in MD stock from 5/31/2026 to 9/4/2026 was primarily driven by a 22.8% change in the company's P/E Multiple.| (LTM values as of) | 5312026 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.54 | 27.03 | 25.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,932 | 1,951 | 1.0% |
| Net Income Margin (%) | 9.0% | 9.0% | -0.6% |
| P/E Multiple | 10.0 | 12.3 | 22.8% |
| Shares Outstanding (Mil) | 81 | 79 | 1.8% |
| Cumulative Contribution | 25.5% |
Market Drivers
5/31/2026 to 9/4/2026| Return | Correlation | |
|---|---|---|
| MD | 25.5% | |
| Market (SPY) | 1.8% | -2.1% |
| Sector (XLV) | 14.7% | 34.4% |
Fundamental Drivers
The 36.2% change in MD stock from 2/28/2026 to 9/4/2026 was primarily driven by a 24.2% change in the company's P/E Multiple.| (LTM values as of) | 2282026 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.85 | 27.03 | 36.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,914 | 1,951 | 1.9% |
| Net Income Margin (%) | 8.6% | 9.0% | 3.7% |
| P/E Multiple | 9.9 | 12.3 | 24.2% |
| Shares Outstanding (Mil) | 82 | 79 | 3.7% |
| Cumulative Contribution | 36.2% |
Market Drivers
2/28/2026 to 9/4/2026| Return | Correlation | |
|---|---|---|
| MD | 36.2% | |
| Market (SPY) | 12.6% | 11.3% |
| Sector (XLV) | 7.5% | 26.6% |
Fundamental Drivers
The 57.1% change in MD stock from 8/31/2025 to 9/4/2026 was primarily driven by a 58.2% change in the company's Net Income Margin (%).| (LTM values as of) | 8312025 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.21 | 27.03 | 57.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,941 | 1,951 | 0.5% |
| Net Income Margin (%) | 5.7% | 9.0% | 58.2% |
| P/E Multiple | 13.3 | 12.3 | -7.5% |
| Shares Outstanding (Mil) | 85 | 79 | 6.7% |
| Cumulative Contribution | 57.1% |
Market Drivers
8/31/2025 to 9/4/2026| Return | Correlation | |
|---|---|---|
| MD | 57.1% | |
| Market (SPY) | 20.4% | 14.1% |
| Sector (XLV) | 26.4% | 27.3% |
Fundamental Drivers
The 91.3% change in MD stock from 8/31/2023 to 9/4/2026 was primarily driven by a 73.8% change in the company's Net Income Margin (%).| (LTM values as of) | 8312023 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.13 | 27.03 | 91.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,995 | 1,951 | -2.2% |
| Net Income Margin (%) | 5.2% | 9.0% | 73.8% |
| P/E Multiple | 11.3 | 12.3 | 8.5% |
| Shares Outstanding (Mil) | 82 | 79 | 3.7% |
| Cumulative Contribution | 91.3% |
Market Drivers
8/31/2023 to 9/4/2026| Return | Correlation | |
|---|---|---|
| MD | 91.3% | |
| Market (SPY) | 77.1% | 22.8% |
| Sector (XLV) | 34.7% | 25.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MD Return | 11% | -45% | -37% | 41% | 63% | 26% | 10% |
| Peers Return | 60% | -16% | 14% | 0% | 15% | 39% | 146% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| MD Win Rate | 50% | 42% | 42% | 67% | 58% | 56% | |
| Peers Win Rate | 77% | 42% | 56% | 50% | 54% | 56% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| MD Max Drawdown | -30% | -48% | -50% | -33% | -30% | -17% | |
| Peers Max Drawdown | -21% | -37% | -31% | -36% | -29% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HCA, THC, CHE, AMN. See MD Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/4/2026 (YTD)
How Low Can It Go
| Event | MD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -15.0% | -18.8% |
| % Gain to Breakeven | 17.6% | 23.1% |
| Time to Breakeven | 15 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -41.3% | -9.5% |
| % Gain to Breakeven | 70.3% | 10.5% |
| Time to Breakeven | 337 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -13.2% | -6.7% |
| % Gain to Breakeven | 15.2% | 7.1% |
| Time to Breakeven | 547 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -70.3% | -33.7% |
| % Gain to Breakeven | 237.0% | 50.9% |
| Time to Breakeven | 315 days | 140 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -10.5% | -6.8% |
| % Gain to Breakeven | 11.7% | 7.3% |
| Time to Breakeven | 16 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -19.0% | -17.9% |
| % Gain to Breakeven | 23.4% | 21.8% |
| Time to Breakeven | 177 days | 123 days |
In The Past
Pediatrix Medical's stock fell -15.0% during the 2025 US Tariff Shock. Such a loss loss requires a 17.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MD | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -41.3% | -9.5% |
| % Gain to Breakeven | 70.3% | 10.5% |
| Time to Breakeven | 337 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -70.3% | -33.7% |
| % Gain to Breakeven | 237.0% | 50.9% |
| Time to Breakeven | 315 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -64.5% | -53.4% |
| % Gain to Breakeven | 181.5% | 114.4% |
| Time to Breakeven | 774 days | 1085 days |
In The Past
Pediatrix Medical's stock fell -15.0% during the 2025 US Tariff Shock. Such a loss loss requires a 17.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Pediatrix Medical (MD)
Pediatrix Medical (MD) is a leading provider of specialized medical care services, primarily focusing on the health of newborns, expectant mothers, and children. The company operates a significant network of approximately 2,700 physicians and clinicians across the United States and Puerto Rico. Essentially, Pediatrix partners with hospitals and healthcare facilities to staff and manage critical care services for its target patient populations.
The company's core services include comprehensive neonatal care for prematurely born or complicated babies, delivered by physician subspecialists and nurse practitioners within hospital units. It also offers extensive maternal-fetal care, providing inpatient and office-based clinical services to expectant mothers and unborn babies through a team of maternal-fetal medicine subspecialists, obstetricians, and other clinicians. Furthermore, Pediatrix specializes in pediatric cardiology, delivering care for congenital and acquired heart defects in patients ranging from fetuses to adolescents, and even adults with congenital conditions.
Beyond these primary offerings, Pediatrix Medical extends its services into various other pediatric subspecialties, utilizing experts like pediatric intensivists, hospitalists, surgeons, ophthalmologists, and ear, nose, and throat physicians. The company also provides vital support services within hospitals, particularly in pediatric emergency rooms, labor and delivery areas, and pediatric departments. Its primary customers are the hospitals and healthcare systems that contract with Pediatrix to provide these specialized physician and clinical services, ultimately serving patients in need of complex maternal, fetal, and pediatric care.
AI Analysis | Feedback
Here are 1-2 brief analogies for Pediatrix Medical (MD):
- Pediatrix Medical is like TeamHealth for women's and children's subspecialty doctors, providing specialized medical staffing and management for hospitals.
- It's a national network of maternal-fetal and pediatric specialists, similar to how DaVita is a national network for kidney dialysis.
AI Analysis | Feedback
- Neonatal Care Services: Provides clinical care for premature or complicated babies within hospital units, delivered by neonatal physician subspecialists and nurse practitioners.
- Maternal-Fetal Care Services: Offers inpatient and office-based clinical care to expectant mothers and unborn babies through maternal-fetal medicine subspecialists and other clinicians.
- Pediatric Cardiology Care Services: Delivers inpatient and office-based care for fetuses, infants, children, and adolescents with congenital heart defects and acquired heart disease.
- Other Pediatric Subspecialty Care Services: Includes specialized care from pediatric intensivists, hospitalists, surgeons, ophthalmologists, and ear, nose, and throat physicians.
- Hospital Support Services: Provides support in areas such as pediatric emergency rooms, labor and delivery, and nursery/pediatric departments within hospitals.
AI Analysis | Feedback
Pediatrix Medical (symbol: MD) primarily provides medical care services directly to individuals.
Its major customer categories include:
- Newborns and Infants: Patients receiving neonatal care due to prematurity or complications.
- Expectant Mothers and Unborn Babies: Patients receiving maternal-fetal care, including inpatient and office-based clinical care.
- Children and Adolescents: Patients receiving pediatric cardiology care for congenital or acquired heart defects, as well as care from other pediatric subspecialists such as intensivists, hospitalists, surgeons, ophthalmologists, and ear, nose, and throat physicians.
AI Analysis | Feedback
AI Analysis | Feedback
Mark S. Ordan, Chair of the Board of Directors and Chief Executive Officer
Mark S. Ordan was appointed Chair of the Board of Directors and Chief Executive Officer of Pediatrix Medical Group in January 2025, having previously served as CEO from July 2020 to December 2022 and then as Executive Chair of the Board. He is recognized for his extensive experience in transforming business operations. Mr. Ordan founded and served as CEO of Fresh Fields Market, which he later merged with Whole Foods Market in 1996. He has held numerous CEO roles at other public companies, including Quality Care Properties, Inc., Washington Prime Group Inc., Sunrise Senior Living, Inc., The Mills Corporation, and Balducci's. Notably, he was instrumental in the sale of The Mills Corporation to Simon Property Group and Farallon Capital Management in 2007, and he led the turnaround and sale of Sunrise Senior Living, Inc. to Health Care REIT and KKR in 2013. His leadership at Quality Care Properties, Inc. also culminated in its sale to Welltower Inc. and ProMedica Health System. Mr. Ordan currently serves on the Board of Directors of The Carlyle Group as Lead Independent Director, demonstrating a pattern of managing or being involved with companies backed by private equity firms.
Kasandra Rossi, Executive Vice President, Chief Financial Officer and Treasurer
Kasandra Rossi was appointed Executive Vice President, Chief Financial Officer and Treasurer in October 2024. She joined Pediatrix in December 2009 and has held various senior-level accounting, finance, and treasury positions within the company, including Senior Vice President, Financial Reporting and Assistant Treasurer. Before joining Pediatrix, Ms. Rossi served in accounting and finance roles at other public companies in South Florida, such as Office Depot, Inc. and Republic Services, Inc., from July 2003 to December 2009. From September 1999 to July 2003, she was a member of the assurance practice of Ernst & Young, LLP, providing services to clients in various industries, including healthcare, private equity, and aviation.
Mary Ann E. Moore, Executive Vice President, General Counsel, Chief Administrative Officer and Secretary
Mary Ann E. Moore assumed the role of Chief Administrative Officer in August 2024, in addition to her existing appointments as Executive Vice President, General Counsel, and Secretary since October 2022. She joined Pediatrix in 2006 as Associate General Counsel and has since held several senior positions within the Legal Department. Prior to her tenure at Pediatrix, Ms. Moore served as Senior Counsel for Tenet Healthcare Corporation in South Florida. Her background also includes experience with Adventist Health System and in private legal practice.
Greg Neeb, Executive Vice President, Chief Investment and Strategy Officer
Greg Neeb was appointed Executive Vice President, Chief Investment and Strategy Officer in August 2025. He is the founder of Neeb Management LLC and Neeb Investments LLC, healthcare and real estate advisory and investment firms established in 2013. Mr. Neeb’s extensive experience includes serving as President and Chief Investment Officer of Quality Care Properties, Inc. from 2016 to 2018, which was later sold to Welltower Inc. and ProMedica Health System. From 2008 to 2013, he was the Chief Investment and Administrative Officer for Sunrise Senior Living, Inc., playing a key role in its sale to Welltower Inc. and Kohlberg Kravis Roberts & Co. LP. Earlier in his career, from 1995 to 2007, Mr. Neeb was Chief Investment Officer for The Mills Corporation, which was sold to Simon Property Group and Farallon Capital Management. His background demonstrates a consistent involvement in managing and selling companies, including those with private equity backing.
Nanette Sanders, Executive Vice President, National Operations
Nanette Sanders serves as the Executive Vice President of National Operations for Pediatrix Medical Group. She joined the company in 1997, when it was known as Mednax, as a Regional Manager for the Managed Care Division. Throughout her career at Pediatrix, Ms. Sanders has held various leadership roles, including Regional President, West Coast, Regional Vice President, West Market, and Director of Operations in the Pacific Region. She brings over 35 years of experience in the healthcare industry, encompassing hospitals, private practices, and managed care sectors.
AI Analysis | Feedback
Key Risks to Pediatrix Medical (MD)
- Reliance on Highly Specialized Medical Professionals: Pediatrix Medical's business model depends heavily on recruiting and retaining a broad network of highly specialized medical professionals, including neonatal physician subspecialists, maternal-fetal medicine subspecialists, pediatric cardiologists, and other pediatric subspecialists. A shortage of these professionals, increased competition for their services, or challenges in retention could significantly impact the company's ability to deliver care and grow its services.
- Dependence on Hospital Contracts: The company provides its services primarily within specific units at hospitals, including pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. This indicates a substantial reliance on contracts with hospitals. The loss of significant hospital contracts, inability to renew existing agreements on favorable terms, or pressure on contract pricing could materially affect the company's operations and financial performance.
- Changes in Healthcare Reimbursement Policies and Regulations: As a healthcare services provider, Pediatrix Medical is susceptible to changes in government and private insurance reimbursement policies, including reductions in reimbursement rates, changes in coverage criteria, or shifts in payment models. Additionally, evolving healthcare regulations could increase compliance costs or restrict operational flexibility, negatively impacting profitability and service delivery.
AI Analysis | Feedback
AI Analysis | Feedback
Neonatal Care Services
The U.S. neonatal infant care market was valued at approximately $854.7 million in 2024 and is projected to reach $1,570 million by 2034, growing at a compound annual growth rate (CAGR) of 6.8%.Maternal-Fetal Care Services
The U.S. fetal monitoring market, which includes maternal-fetal care services, was estimated at $1.55 billion in 2024 and is expected to reach around $3.02 billion by 2034, exhibiting a CAGR of 6.90% from 2025 to 2034.Pediatric Cardiology Care Services
The U.S. Pediatric Cardiology market is projected to be $0.97 billion in 2024 and is expected to grow to $1.46 billion by 2030, with a CAGR of 7.1%. The U.S. pediatric interventional cardiology market is projected to grow from $1.2 billion in 2024 to $2.4 billion by 2034.Other Pediatric Subspecialty Care Services
The broader U.S. pediatric healthcare market, encompassing various pediatric subspecialty care services, was estimated at $4.18 billion in 2024 and is projected to reach approximately $9.50 billion by 2034, growing at a CAGR of 8.56% from 2025 to 2034.AI Analysis | Feedback
Pediatrix Medical (MD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
- Favorable Payer Mix and Increased Patient Acuity: The company anticipates continued benefit from a favorable payer mix and higher patient acuity within its neonatology segment. This leads to improved reimbursement-related factors and growth in same-unit pricing, contributing to top-line performance despite potential flat patient volumes.
- Strategic Acquisitions: Pediatrix Medical is pursuing an inorganic growth strategy, focusing on strategic acquisitions in its core and adjacent service areas to expand its capacity and patient volumes. The company is actively exploring further practice acquisitions and expansion opportunities.
- Expansion of Core Specialties and Telemedicine: The company is committed to expanding its presence within core specialties, including Neonatal Intensive Care Units (NICUs), maternal-fetal medicine, and OB hospital medicine programs. Additionally, Pediatrix Medical is exploring growth opportunities through the strategic use of telemedicine.
- Enhanced Revenue Cycle Management (RCM) and Contract Administrative Fees: Improvements in revenue cycle management collections, coupled with an favorable payer mix, increased patient acuity, and higher contract administrative fees from hospital partners, are expected to support an increase in net patient service revenues, even if patient volumes and general pricing remain stable.
AI Analysis | Feedback
Share Repurchases
- Pediatrix Medical Group authorized a share repurchase program of up to $250 million of its outstanding common stock on August 18, 2025, with a three-year term.
- The company used $64.0 million for share repurchases in the fourth quarter of 2025, which reduced shares outstanding to approximately 83 million.
- Pediatrix Medical Group also used $20.9 million for share repurchases in the third quarter of 2025.
Share Issuance
- On March 1, 2026, an executive vice president received 39,925 shares as a performance-based award from a program established in March 2023, with 26,931 shares withheld for tax obligations upon vesting.
- The weighted average shares outstanding for the year ended December 31, 2025, was 85.3 million, compared to 83.3 million for 2024.
- Weighted average shares outstanding were 82.2 million for the year ended December 31, 2023.
Outbound Investments
- Pediatrix Medical Group utilized $19.2 million for acquisition activity in the third quarter of 2025.
- The company used $5.0 million to fund a practice acquisition in the fourth quarter of 2023.
- In 2024, Pediatrix Medical Group added one maternal-fetal medicine practice while completing plans to exit most office-based practices and its primary and urgent care service lines.
Capital Expenditures
- Pediatrix Medical Group’s capital expenditures were $5.3 million in the fourth quarter of 2025 and $5.3 million in the third quarter of 2025.
- The company reported $3.4 million in capital expenditures for the fourth quarter of 2024.
- Capital expenditures totaled $9.0 million in the fourth quarter of 2023.
Peer Outperformance in Health Care Services
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 13.9% | 96.3% | 127.8% | CAH 414% · MCK 351% · COR 179% |
| Managed Health Care | 8 | 33.2% | 1.7% | 3.3% | OSCR 77% · HQY 48% · ELV 16% |
| Health Care Services ← | 20 | 21.0% | 52.1% | -1.5% | HIMS 238% · RDNT 134% · DGX 68% |
| Health Care Facilities | 24 | 1.8% | 4.9% | -19.0% | THC 249% · NHC 244% · ENSG 108% |
| Health Care Equipment | 50 | -5.3% | -4.8% | -24.0% | POCI 10775% · UFPT 318% · GKOS 200% |
| Health Care Supplies | 12 | 32.3% | -14.4% | -35.5% | LNTH 272% · HAE 59% · MMSI 23% |
| Pharmaceuticals | 63 | -0.9% | 0.6% | -36.4% | LQDA 2406% · INDV 1148% · ETON 1022% |
| Life Sciences Tools & Services | 109 | 2.4% | -28.7% | -73.9% | SNWV 1688% · MEDP 203% · AXGN 178% |
| Biotechnology | 363 | 8.8% | -25.7% | -76.8% | BRTX 73900% · DNTH 1558% · CELZ 1486% |
| Health Care Technology | 20 | -25.0% | -56.7% | -78.6% | SPOK 68% · HSTM -2% · VEEV -13% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Pediatrix Medical Earnings Notes | 12/31/2026 | |
| Should You Buy Pediatrix Medical Stock? | 11/04/2025 | |
| How Low Can Pediatrix Medical Stock Really Go? | 10/17/2025 | |
| Pediatrix Medical (MD) Debt Comparison | 08/08/2025 | |
| Pediatrix Medical (MD) Operating Cash Flow Comparison | 08/08/2025 | |
| Pediatrix Medical (MD) EBITDA Comparison | 08/08/2025 | |
| ARTICLES | ||
| Is Pediatrix Medical Stock Outperforming Its Rivals? | 11/04/2025 | |
| Buy or Sell Pediatrix Medical Stock? | 11/04/2025 | |
| What’s Next For Mednax Stock After The Recent 20% Rally? | 07/01/2021 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 265.05 |
| Mkt Cap | 6.8 |
| Rev LTM | 3,434 |
| Op Inc LTM | 352 |
| FCF LTM | 439 |
| FCF 3Y Avg | 316 |
| CFO LTM | 471 |
| CFO 3Y Avg | 372 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.3% |
| Rev Chg 3Y Avg | 4.5% |
| Rev Chg Q | 8.7% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Inc Chg LTM | 13.0% |
| Op Inc Chg 3Y Avg | 12.1% |
| Op Mgn LTM | 13.6% |
| Op Mgn 3Y Avg | 14.6% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 14.3% |
| CFO/Rev 3Y Avg | 14.1% |
| FCF/Rev LTM | 12.5% |
| FCF/Rev 3Y Avg | 9.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 6.8 |
| P/S | 1.1 |
| P/Op Inc | 8.2 |
| P/EBIT | 7.3 |
| P/E | 12.6 |
| P/CFO | 8.0 |
| Total Yield | 8.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 14.5% |
| D/E | 0.6 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 1.3% |
| 3M Rtn | 17.9% |
| 6M Rtn | 27.8% |
| 12M Rtn | 37.7% |
| 3Y Rtn | 51.2% |
| 1M Excs Rtn | 1.8% |
| 3M Excs Rtn | 13.3% |
| 6M Excs Rtn | 13.3% |
| 12M Excs Rtn | 19.0% |
| 3Y Excs Rtn | -22.8% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Physician services including newborn, maternal-fetal, and other pediatric subspecialty care | 1,914 | 2,013 | 1,995 | ||
| Hospital contract administrative fees | 263 | ||||
| Maternal-fetal medicine | 270 | 344 | |||
| Neonatology and other pediatric subspecialties | 1,419 | 1,472 | |||
| Other revenue | 20 | ||||
| Pediatric cardiology | 96 | ||||
| Total | 1,914 | 2,013 | 1,995 | 1,972 | 1,911 |
Price Behavior
| Market Price | $27.03 | |
| Market Cap ($ Bil) | 2.1 | |
| First Trading Date | 09/20/1995 | |
| Distance from 52W High | -1.3% | |
| 50 Days | 200 Days | |
| DMA Price | $26.03 | $22.92 |
| DMA Trend | up | up |
| Distance from DMA | 3.8% | 17.9% |
| 3M | 1YR | |
| Volatility | 36.5% | 42.5% |
| Downside Capture | -53.42 | 37.41 |
| Upside Capture | 38.99 | 83.37 |
| Correlation (SPY) | -2.5% | 14.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.33 | -0.28 | -0.05 | 0.30 | 0.48 | 0.70 |
| Up Beta | -2.94 | -1.90 | -0.76 | 0.19 | 0.22 | 0.57 |
| Down Beta | -0.37 | 0.52 | 0.37 | 0.53 | 0.31 | 0.75 |
| Up Capture | -49% | 14% | 47% | 48% | 76% | 55% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 10 | 19 | 35 | 71 | 137 | 388 |
| Down Capture | -60% | 16% | -54% | -7% | 51% | 89% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 10 | 22 | 28 | 55 | 112 | 352 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MD | |
|---|---|---|---|---|
| MD | 59.2% | 42.5% | 1.19 | - |
| Sector ETF (XLV) | 26.5% | 16.0% | 1.28 | 27.1% |
| Equity (SPY) | 19.7% | 12.8% | 1.13 | 14.0% |
| Gold (GLD) | 24.6% | 29.2% | 0.75 | 5.0% |
| Commodities (DBC) | 44.1% | 20.4% | 1.69 | -9.6% |
| Real Estate (VNQ) | 9.1% | 13.6% | 0.39 | 22.2% |
| Bitcoin (BTCUSD) | -26.9% | 43.8% | -0.59 | -5.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MD | |
|---|---|---|---|---|
| MD | -4.3% | 44.2% | 0.03 | - |
| Sector ETF (XLV) | 6.6% | 15.1% | 0.25 | 31.0% |
| Equity (SPY) | 12.8% | 17.2% | 0.57 | 32.2% |
| Gold (GLD) | 19.1% | 18.8% | 0.82 | 3.1% |
| Commodities (DBC) | 10.7% | 19.5% | 0.43 | 3.3% |
| Real Estate (VNQ) | 1.7% | 18.9% | -0.01 | 33.5% |
| Bitcoin (BTCUSD) | 10.6% | 52.6% | 0.38 | 14.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MD | |
|---|---|---|---|---|
| MD | -8.0% | 46.1% | -0.01 | - |
| Sector ETF (XLV) | 10.8% | 16.7% | 0.53 | 31.5% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 36.6% |
| Gold (GLD) | 12.4% | 16.3% | 0.62 | 0.2% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | 13.9% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.19 | 37.8% |
| Bitcoin (BTCUSD) | 64.0% | 66.2% | 1.04 | 10.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 9/4/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | -5.9% | -0.6% | 0.8% |
| 5/5/2026 | -7.1% | 4.3% | -2.5% |
| 2/19/2026 | -12.2% | -9.4% | -9.5% |
| 11/3/2025 | 24.2% | 29.2% | 37.2% |
| 8/5/2025 | 5.0% | 14.8% | 35.0% |
| 5/6/2025 | 11.8% | 10.9% | 7.3% |
| 2/20/2025 | 22.1% | 6.3% | 0.3% |
| 11/1/2024 | 23.5% | 30.2% | 21.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 12 | 12 |
| # Negative | 11 | 12 | 12 |
| Median Positive | 11.8% | 13.1% | 13.2% |
| Median Negative | -8.9% | -8.0% | -10.1% |
| Max Positive | 24.2% | 32.9% | 56.3% |
| Max Negative | -24.7% | -19.3% | -23.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | -5.9% | -0.6% | 0.8% |
| 5/5/2026 | -7.1% | 4.3% | -2.5% |
| 2/19/2026 | -12.2% | -9.4% | -9.5% |
| 11/3/2025 | 24.2% | 29.2% | 37.2% |
| 8/5/2025 | 5.0% | 14.8% | 35.0% |
| 5/6/2025 | 11.8% | 10.9% | 7.3% |
| 2/20/2025 | 22.1% | 6.3% | 0.3% |
| 11/1/2024 | 23.5% | 30.2% | 21.8% |
| 8/6/2024 | 17.7% | 32.9% | 38.3% |
| 5/7/2024 | -2.5% | -8.1% | -23.0% |
| 2/20/2024 | -8.9% | -4.3% | 2.0% |
| 11/2/2023 | -11.8% | -14.2% | -21.8% |
| 8/3/2023 | 6.7% | 6.5% | 2.3% |
| 5/2/2023 | 2.9% | -4.2% | -7.2% |
| 2/17/2023 | 10.9% | 3.8% | -3.4% |
| 11/3/2022 | -18.5% | -19.3% | -12.6% |
| 8/4/2022 | -13.5% | -6.0% | -20.9% |
| 4/28/2022 | -8.9% | -16.0% | -15.1% |
| 2/17/2022 | -6.1% | -8.0% | -6.9% |
| 10/28/2021 | 0.8% | -1.8% | -10.7% |
| 8/6/2021 | 9.3% | 11.4% | 2.1% |
| 5/7/2021 | 20.0% | 15.3% | 19.1% |
| 2/18/2021 | -24.7% | -13.8% | -0.9% |
| 11/6/2020 | 17.5% | 31.6% | 56.3% |
| SUMMARY STATS | |||
| # Positive | 13 | 12 | 12 |
| # Negative | 11 | 12 | 12 |
| Median Positive | 11.8% | 13.1% | 13.2% |
| Median Negative | -8.9% | -8.0% | -10.1% |
| Max Positive | 24.2% | 32.9% | 56.3% |
| Max Negative | -24.7% | -19.3% | -23.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 11/01/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/04/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 02/19/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 11/01/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 04/28/2022 | 10-Q |
| 12/31/2021 | 02/17/2022 | 10-K |
| 09/30/2021 | 10/28/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 02/18/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 07/30/2020 | 10-Q |
| 03/31/2020 | 05/07/2020 | 10-Q |
| 12/31/2019 | 02/20/2020 | 10-K |
| 09/30/2019 | 11/01/2019 | 10-Q |
Recent Forward Guidance
Updated 8/5/2026Latest: Q2 2026 Earnings Reported 8/4/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted EBITDA | Reported | 280.00 Mil | 290.00 Mil | 300.00 Mil | 0 | Affirmed | Guidance: 290.00 Mil for 2026 | |
Prior: Q1 2026 Earnings Reported 5/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted EBITDA | Reported | 280.00 Mil | 290.00 Mil | 300.00 Mil | 0 | Affirmed | Guidance: 290.00 Mil for 2026 | |
Q4 2025 Earnings Reported 2/19/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted EBITDA | Reported | 280.00 Mil | 290.00 Mil | 300.00 Mil | 3.6% | Higher New | Guidance: 280.00 Mil for 2025 | |
Q3 2025 Earnings Reported 11/3/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Adjusted EBITDA | Reported | 270.00 Mil | 280.00 Mil | 290.00 Mil | 12.0% | Raised | Guidance: 250.00 Mil for 2025 | |
Insider Activity
Updated 8/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Weis, Shirley A | The Weis Family Trust U/A dtd 04/19/2002, John N. Weis & Shirley A. Weis Trustees | Sell | 5142026 | 23.75 | 36,028 | Form | |||
| 2 | Ordan, Mark S | Chief Executive Officer | Direct | Sell | 12172025 | 22.41 | 23,000 | 515,430 | 6,785,860 | Form |
| 3 | Rucker, Michael A | Direct | Sell | 11192025 | 23.00 | 10,478 | 240,994 | 1,359,323 | Form | |
| 4 | Linynsky, Laura A | Direct | Sell | 11102025 | 21.65 | 10,000 | 216,500 | 697,823 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Weis, Shirley A | The Weis Family Trust U/A dtd 04/19/2002, John N. Weis & Shirley A. Weis Trustees | Sell | 5142026 | 23.75 | 36,028 | Form | |||
| 2 | Ordan, Mark S | Chief Executive Officer | Direct | Sell | 12172025 | 22.41 | 23,000 | 515,430 | 6,785,860 | Form |
| 3 | Rucker, Michael A | Direct | Sell | 11192025 | 23.00 | 10,478 | 240,994 | 1,359,323 | Form | |
| 4 | Linynsky, Laura A | Direct | Sell | 11102025 | 21.65 | 10,000 | 216,500 | 697,823 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Services Resources |
| HealthLeaders Media |
| Medical Economics |
| Physicians Practice |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.